Optinose Story

<div class='circular--portrait' style='background:#4E8BFC;color: #ffffff;font-size:4em;'>OP</div>
OPTN -- USA Stock  

USD 3.50  0.01  0.29%

While some traders are getting carried away by overanalyzing healthcare space, it is reasonable to outline Optinose against current market trends. As we have suggested previously, Optinose is beginning its slide as institutional investors shift to be more bearish due to the increased sector volatility. Plenty of the changes of the company stock price movements has been a rough indication of what is happening in the market overall. Conflicting basic indicators of the company may also entail signs of long-standing losses for Optinose institutional investors. Optinose is scheduled to announce its earnings today. The next earnings report is expected on the 4th of March 2021.
Published over a month ago
View all stories for Optinose | View All Stories
Should you take over Optinose (NASDAQ:OPTN) based on latest technical indicators?
This firm's average rating is Strong Buy from 4 analysts. Do analysts base this consensus on technical analyses? We know that typical technical analysis utilizes price momentum, patterns, and trends looking at historical prices. It aims to identify signals based on Optinose market sentiment investors' perception of the future value of Optinose. Let us look at a few aspects of Optinose technical analysis. About 94.0% of the company shares are owned by institutional investors. Optinose recorded a loss per share of 2.19. The entity had not issued any dividends in recent years.
Using predictive technical analysis, we will analyze different prices and returns patterns and diagnose historical swings to determine the real value of Optinose. In general, we focus on analyzing Optinose stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Optinose's daily price indicators and compare them against related drivers such as momentum indicators and various other types of predictive indicators. Using this methodology combined with a more conventional technical analysis and fundamental analysis, we attempt to find the most accurate representation of Optinose's intrinsic value. In addition to deriving basic predictive indicators for Optinose, we also check how macroeconomic factors affect Optinose price patterns. Please read more on our technical analysis page or use our predictive modules below to complement your research.
Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of Optinose's stock price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of Optinose in the context of predictive analytics.
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Optinose. Your research has to be compared to or analyzed against Optinose's peers to derive any actionable benefits. When done correctly, Optinose's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy towards taking a position in Optinose.

How does Optinose Stands against Peers?

Analyzing Optinose competition or peers my help you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Try to analyze the advantages of investing in traded instruments related to Optinose across multiple sectors and thematic ideas. A good competitive analysis can cover a lot of different areas. But what areas to choose depends on who you are. The more exhaustive you are in your analysis, the more effective your competitive analysis will be.
Check out Optinose Competition Details

How Optinose utilizes its cash?

To perform a cash flow analysis of Optinose, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Optinose is receiving and how much cash it distributes out in a given period. The Optinose cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.

Purchase by Peter Miller of 11742 shares of Optinose

Legal trades by Optinose insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Optinose insider trading alert for perchase of common stock by Peter Miller, Chief Executive Officer, on 22nd of March 2021. This event was filed by Optinose Inc with SEC on 2021-03-22. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Detailed Perspective On Optinose

The company has a beta of 1.417. Let's try to break down what Optinose's beta means in this case. Optinose returns are very sensitive to returns on the market. As the market goes up or down, Optinose is expected to follow. The beta indicator helps investors understand whether Optinose moves in the same direction as the rest of the market, and how volatile (i.e., risky) it is compared to the market (i.e., selected benchmark). In other words, if Optinose deviates very little from the market, it does not add much risk to the portfolio, but it also doesn't increase the expected returns. Optinose reported the previous year's revenue of 43.85 M. Net Loss for the year was (100.92 M) with profit before overhead, payroll, taxes, and interest of 29.34 M.

Analysis of Optinose

Latest total risk alpha indicator falls down to -0.45. Possible price upswing?
As of the 3rd of March, Optinose holds the risk adjusted performance of (0.010538), and Coefficient Of Variation of (4,225). Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Optinose, as well as the relationship between them. Put it differently, you can use this information to find out if the company will indeed mirror its model of past market data, or the prices will eventually revert. We were able to interpolate nineteen technical drivers for Optinose, which can be compared to its competitors. Please check Optinose information ratio, potential upside, as well as the relationship between the Potential Upside and kurtosis to decide if Optinose is priced some-what accurately, providing market reflects its current price of 3.92 per share. Given that Optinose has jensen alpha of (0.20), we recommend you to check out Optinose's recent market performance to make sure the company can sustain itself at a future point.

Our Conclusion on Optinose

Whereas some firms in the drug manufacturers?specialty & generic industry are either recovering or due for a correction, Optinose may not be performing as strong as the other in terms of long-term growth potentials. To summarize, as of the 3rd of March 2021, our analysis shows that Optinose responds to the market. The company is undervalued and projects significantly high chance of financial distress for the next 2 years. However, our concluding 30 days buy-hold-sell advice on the company is Sell.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of Optinose. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com